COVIDNews CEPTON-INATO #3

17 April 2020 - By Marc-Olivier Bévierre

The number of interventional trials is still rising, with now 30 trials that will include more than 1,000 patients each. The most tested drugs remain Hydoxychloroquine and antivirals.
We also provide insights on the modes of action of the different drugs tested, thanks to a James M. Sanders et al.

CEPTON Strategies news

Here are all the reports and analysis we published along with the press articles about us

CEPTON is the author of many publications in the field of healthcare and pharmaceuticals and our partners are often interviewed by the specialized press.

Connected medical devices embedded in AI: the wave is coming

Posted on 14.01.2021 by Marc-Olivier Bévierre

See more

Objets connectés

Posted on 14.01.2021 by Marc-Olivier Bévierre

See more

CEPTON strengthens its management team in Paris and appoints 3 new Associate Partners

Posted on 28.10.2020 by Marc-Olivier Bévierre

See more

CEPTON-INATO COVID-19 Clinical Trials Newsletter #5

Posted on 07.05.2020 by Marc-Olivier Bévierre

See more

CEPTON-INATO COVID-19 Clinical Trials Newsletter #4

Posted on 24.04.2020 by Marc-Olivier Bévierre

See more

COVIDNews CEPTON-INATO #3

Posted on 17.04.2020 by Marc-Olivier Bévierre

See more

Contact us

You have a question, an issue you would like to share with us

Feel free to contact us to arrange a meeting or a teleconference, using the form below.

You would like to apply for a job with us

We are always happy to welcome new profiles in our teams, please fill the following form to apply for a job in CEPTON.